The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
CpG island methylator phenotype and KRAS mutation status as prognostic markers in patients with resected colorectal cancer.
D. H. Koo
No relevant relationships to disclose
Y. S. Hong
No relevant relationships to disclose
K. Kim
No relevant relationships to disclose
J. Lee
No relevant relationships to disclose
H. Chang
No relevant relationships to disclose
Y. Kang
No relevant relationships to disclose
C. S. Yu
No relevant relationships to disclose
J. C. Kim
No relevant relationships to disclose
M. Kim
No relevant relationships to disclose
S. J. Jang
No relevant relationships to disclose
T. W. Kim
No relevant relationships to disclose